Bacterial resistance to ciprofloxacin in Greece: Results from the national electronic surveillance system

Emerging Infectious Diseases

Volumn 5, Issue 3, 1999, Pages 471-476

  Vatopoulos, A C ^a,b   Kalapothaki, V ^a   Legakis, N J ^a   Antoniadis, G ^a   Arhondidou, E ^a   Chatzipanagiotou, S ^a   Chinou, E ^a   Chrysaki, A ^a   Daniilidis, V ^a   Genimata, G ^a   Gessouli, H ^a   Golemati, P ^a   Kaili Papadopoulou, E ^a   Kansuzidou, A ^a   Kailis, D ^a   Kaitsa, E ^a   Kanelopoulou, M ^a   Kitsou Kyriakopoulou, Sp ^a   Komninou, Z ^a   Kouskouni, E ^a   Koutsia Karouzou, Chr ^a   Ktenidou Kartali, S ^a   Liakou, V ^a   Malamou Lada, H ^a   Mercuri, H ^a   Nicolopoulou, C ^a   Pagkali, A ^a   Panagiotou, E ^a   Papafragas, E ^a   Perogamvros, A ^a   Poulopoulou, C ^a   Sofianou, D ^a   Theodoropoulou Rodiou, G ^a   Thermogianni, S ^a   Trikka Graphakos, E ^a   Vavatsi Manou, O ^a   Ventouri, M ^a   Vogiatzakis, E ^a   Xanthaki, A ^a   Zagora, Chr ^a   Chatzidaki, E ^a   Papoutsakis, G ^a   more..

^a UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; DRUG EFFICACY; GREECE; HOSPITAL DEPARTMENT; HOSPITAL INFECTION; INTENSIVE CARE UNIT; MULTIDRUG RESISTANCE; NONHUMAN; OUTPATIENT;

EID: 0033000327     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0503.990325     Document Type: Article

References (22)

1. Blondeau JM, Yaschuk Y, Canadian ciprofloxacin susceptibility study. Comparative study from 15 medical centers. Antimicrob Agents Chemother 1996;40:1729-32.
2. Acar JF, Goldstein FW. Trends in bacterial resistance to fluoroquinolones. Clin Infect Dis 1997;24:S67-73.
3. Report of the American Society for Microbiology Task Force on Antibiotic Resistance. Washington: American Society for Microbiology; 1995. p. 1-23.
4. Stelling JM, O'Brien TF. Surveillance of antimicrobial resistance: the WHONET program. Clin Infect Dis 1997;24:S157-68.
5. Emori TG, Gaynes RP. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin Microbiol Rev 1993;6:428-42.
6. Wartz MN. Hospital-acquired infections: diseases with increasingly limited therapies. Proc Natl Acad Sci U S A1994;91:2420-7.
7. Goldstein FW, Acar JF. Epidemiology of quinolone resistance: Europe and North and South America. Drugs 1995;49:S36-42.
8. Sanders CC, Sanders WE Jr, Thomson. Fluoroquinolone resistance in Staphylococci: new challenges. Eur J Clin Microbiol Infect Dis 1995;Suppl 1:6-11.
9. Legakis NJ, Tzouvelekis LS, Tsakris A, Legakis JN, Vatopoulos AC. On the incidence of antibiotic resistance among aerobic gram-negative rods isolated in Greek hospitals. J Hosp Infect 1993;24:233-7.
10. Kresken M, Hafner D, Mittermayer H, Verbist L, Bergogne-Berezin E, Giamarellou H, et al. Prevalence of fluoroquinolone resistance in Europe. Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy. Infection 1994;22:S90-8.
11. Casellas JM, Blanco MG, Pinto ME. The sleeping giant: antimicrobial resistance. Infect Dis Clin North Am 1994;8:29-45.
12. Tassios PT, Markogiannakis A, Vatopoulos AC, Katsanikou E, Velonakis EN, Kourea-Kremastinou J, et al. Molecular epidemiology of antibiotic resistance of Salmonella enteritidis during a seven year period in Greece. J ClinMicrobiol 1997;35:1316-21.
13. Tassios PT, Vatopoulos AC, Mainas E, Gennimata D, Papadakis J, Tsiftsoglou A, et al. Molecular analysis of ampicillin-resistant sporadic Salmonella typhi and Salmonella paratyphi B clinical isolates. Clinical Microbiology and Infection 1997;3:317-23.
14. Archibald L, Phillips L, Monnet D, McGrowan JE, Tenover F, Gaynes R. Antimicrobial resistance in isolates from inpatients and outpatients in the United States: increasing importance of the intensive care unit. Clin Infect Dis 1997;24:211-5.
15. Vatopoulos AC, Kalapothaki V, Legakis NJ, the Hellenic Antibiotic Resistance Study Group. Risk factors for nosocomial infections caused by gram-negative bacilli. J Hosp Infect 1996,34:11-22.
16. Tassios PT, Gennimata V, Spaliara-Kalogeropoulou L, Kairis D, Koutsia C, Vatopoulos A, et al. Multiresistant Pseudomonas aeruginosa serogroup O:11 outbreak in an intensive care unit. Clinical Microbiology and Infection 1997;3:621-8.
17. Nikaido H. Antibiotic resistance caused by gram-negative multidrug efflux pumps. Clin Infect Dis 1998;Suppl 1:S32-41.
18. Vatopoulos A, Phillipon A, Tsouvelekis L, Komninou Z, Legakis NJ. Prevalence of a transferable SHV-5 type ß-lactamase in clinical isolates of Klebsiella pneumoniae and Escherichia coli in Greece. J Antimicrob Chemother 1990;26:635-48.
19. Tsakris A, Johnson AP, George RC, Mehtar S, Vatopoulos AC. Distribution and transferability of plasmids encoding trimethoprim resistance in urinary pathogens from Greece. J Med Microbiol 1991;34:153-7.
20. Vatopoulos AC, Tsakris A, Tzouvelekis LS, Legakis NJ, Pitt TL, Miller GH, et al. Diversity of aminoglycoside resistance in Enterobacter cloacae in Greece. Eur J Clin Microbiol Infect Dis 1992;11:131-8.
21. Richard P, Delangle MH, Merrien D, Barille S, Reynaud A, Minozzi C, et al. Fluoroquinolone use and fluoroquinolone resistance: Is there an association? Clin Infect Dis 1994;19:54-9.
22. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-60.